GlobeNewswire: Therapeutic Solutions International, Inc. Contains the last 10 of 127 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T03:51:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/09/09/1912797/0/en/Therapeutic-Solutions-International-Reports-NanoStilbene-Protects-the-Immune-System-from-Cancer-Chemotherapy.html?f=22&fvtc=4&fvtv=46044Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy2019-09-09T13:00:00Z<![CDATA[Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address $3.9 Billion Chemotherapy Induced Neutropenia Market Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address $3.9 Billion Chemotherapy Induced Neutropenia Market]]>https://www.globenewswire.com/news-release/2019/09/03/1910082/0/en/Feng-Lin-MD-Ph-D-Joins-Therapeutic-Solutions-International-as-Chief-Scientific-Officer.html?f=22&fvtc=4&fvtv=46044Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer2019-09-03T13:00:00Z<![CDATA[Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA]]>https://www.globenewswire.com/news-release/2019/08/29/1908666/0/en/Therapeutic-Solutions-International-Inc-Reports-Revenues-Up-850-for-Q2.html?f=22&fvtc=4&fvtv=46044Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q22019-08-29T17:53:28Z<![CDATA[OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as compared to the same period in 2018.]]>https://www.globenewswire.com/news-release/2019/08/26/1906525/0/en/Therapeutic-Solutions-International-Announces-Positive-Clinical-Data-Using-NanoStilbene-to-Stimulate-Immune-System-in-Advanced-Cancer-Patients.html?f=22&fvtc=4&fvtv=46044Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients2019-08-26T13:00:00Z<![CDATA[Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal]]>https://www.globenewswire.com/news-release/2019/08/05/1896899/0/en/Therapeutic-Solutions-International-Collaborates-with-Right-to-Try-Foundation-on-Novel-Means-of-Protecting-Patients-While-Hyper-accelerating-Drug-Development.html?f=22&fvtc=4&fvtv=46044Therapeutic Solutions International Collaborates with Right to Try Foundation on Novel Means of Protecting Patients While Hyper-accelerating Drug Development2019-08-05T13:00:00Z<![CDATA[Company Plans to Advance its Phase I Cancer Immunotherapy StemVacs™ to US Patients Company Plans to Advance its Phase I Cancer Immunotherapy StemVacs™ to US Patients]]>https://www.globenewswire.com/news-release/2019/07/29/1892915/0/en/NanoStilbene-Nutraceutical-Shown-to-Increase-Ability-of-Cyclophosphamide-Chemotherapy-to-Suppress-Cancer.html?f=22&fvtc=4&fvtv=46044NanoStilbene™ Nutraceutical Shown to Increase Ability of Cyclophosphamide Chemotherapy to Suppress Cancer2019-07-29T13:00:00Z<![CDATA[Recent Data Supports Investigation of Commercially Available Product as an Adjuvant to Chemotherapy for Cancer Recent Data Supports Investigation of Commercially Available Product as an Adjuvant to Chemotherapy for Cancer]]>https://www.globenewswire.com/news-release/2019/07/22/1885810/0/en/Therapeutic-Solutions-International-Reports-its-NanoStilbene-Nutraceutical-Product-Enhances-Efficacy-of-FDA-Cleared-Cancer-Immunotherapy-in-Animal-Model-of-Cancer.html?f=22&fvtc=4&fvtv=46044Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer2019-07-22T13:00:00Z<![CDATA[New Data Supports Development of Patented Formulation of Blueberry Extract Pterostilbene as an Adjuvant to Immuno-Oncology Treatments New Data Supports Development of Patented Formulation of Blueberry Extract Pterostilbene as an Adjuvant to Immuno-Oncology Treatments]]>https://www.globenewswire.com/news-release/2019/07/15/1882678/0/en/Therapeutic-Solutions-International-adds-Nano-Cannabidiol-to-NanoMyros-for-Inhibition-of-Microvesicle-and-Exosome-Release-in-Prostate-Cancer.html?f=22&fvtc=4&fvtv=46044Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer2019-07-15T13:00:00Z<![CDATA[OCEANSIDE, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Therapeutic Solutions International, Inc. (OTC Markets: TSOI) announced today the addition of nano particle cannabidiol to NanoMyros in the form of its proprietary product Nano Cannabidiol.]]>https://www.globenewswire.com/news-release/2019/07/11/1881456/0/en/Therapeutic-Solutions-International-Develops-Adjuvant-Technology-to-Enhance-Prostate-Cancer-Suppressing-Properties-of-NanoPSA.html?f=22&fvtc=4&fvtv=46044Therapeutic Solutions International Develops Adjuvant Technology to Enhance Prostate Cancer Suppressing Properties of NanoPSA2019-07-11T13:00:00Z<![CDATA[Company Reports Synergistic Activation of Anti-Cancer Protein NRF2 By Proprietary Combination Approach Company Reports Synergistic Activation of Anti-Cancer Protein NRF2 By Proprietary Combination Approach]]>https://www.globenewswire.com/news-release/2019/07/08/1879502/0/en/Therapeutic-Solutions-International-Develops-Glucoraphanin-NanoStilbene-Encapsulated-product-for-reduction-of-Prostate-Specific-Antigen-PSA.html?f=22&fvtc=4&fvtv=46044Therapeutic Solutions International Develops Glucoraphanin + NanoStilbene Encapsulated product for reduction of Prostate Specific Antigen (PSA)2019-07-08T13:00:00Z<![CDATA[OCEANSIDE, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today the development of a broccoli sprout extract containing the precursor glucoraphanin in a combined 200mg dose of NanoStilbene.]]>